2.460USD+1.65%Mkt Cap: 6.15M USDP/E: —Last update: 2026-05-26
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormo…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap6.15M USD
Enterprise Value4.49M USD
Revenue (TTM)5.00K USD
Gross Profit-1.36M USD
Net Income (TTM)-4.18M USD
Revenue/Share0.0030 USD
Last Price2.460 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.95
PEG0.58
EV/EBITDA-1.06
EV/Revenue897.86
P/S1138.72
P/B1.86
EPS (TTM)-2.12
EPS (Forward)-0.60
52W Range
1.67017% of range6.200
52W High6.200 USD
52W Low1.670 USD
Profitability
Gross Margin0.00%
Oper. Margin-30233.33%
EBITDA Margin0.00%
Profit Margin-83520.00%
ROE-193.96%
ROA-140.80%
Growth
Revenue Growth-25.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.87M USD
CapEx (TTM)98.00K USD
FCF Margin-15072.50%
FCF Yield-12.25%
Net Debt-1.39M USD
Net Debt/EBITDA0.33
Balance Sheet
Debt/Equity—
Current Ratio2.44
Quick Ratio1.71
Book Value/Sh1.271 USD
Cash/Share0.5820 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJul 18, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.40M
Float1.87M
Insiders14.11%
Institutions6.64%
Short Interest
Short Ratio0.5d
Short % Float0.40%
Short % Out.0.36%
Shares Short8.71K
Short (prev mo.)14.16K
Technical
SMA 502.820 (-12.8%)
SMA 2002.885 (-14.7%)
Beta-1.13
S&P 52W Chg28.31%
Avg Vol (30d)12.88K
Avg Vol (10d)10.91K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—